News
-
-
-
COMMUNIQUÉ DE PRESSE
MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition
MIRA Pharmaceuticals announced new preclinical results for SKNY-1, an oral drug candidate targeting obesity and nicotine addiction, showing promise in reducing anxiety-like effects. The drug may offer a novel treatment approach for weight loss and craving management -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
MIRA Pharmaceuticals announces positive preclinical data for Mira-55, a non-opioid therapy showing morphine-comparable pain relief without local inflammation. The DEA confirms non-controlled status -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition
MIRA announces promising results of new dual-activity oral therapy SKNY-1 in weight loss and smoking cessation models without muscle loss. The therapy targets CNS side effects -
